Skip to main content

Table 1 New HCv therapies in the pipeline

From: New hepatitis C therapies in clinical development

Drug name Company Target / Active drug Study phase
NS3/4A protease inhibitors    
Ciluprevir (BILN 2061) Boehringer Ingelheim Active site / macrocyclic Stopped
Boceprevir (SCH503034) Merck Active site / linear Phase 3
Telaprevir (VX-950) vertex Active site / linear Phase 3
Danoprevir (RG7227) Roche Active site / macrocyclic Phase 2
TMC435 Tibotec / Medivir Active site / macrocyclic Phase 2
Vaniprevir (MK-7009) Merck Active site / macrocyclic Phase 2
BI 201335 Boehringer Ingelheim Active site / linear Phase 2
BMS-650032 Bristol-Myers Squibb Active site Phase 2
GS-9256 Gilead Active site Phase 2
ABT-450 Abbott / Enanta Active site Phase 2
Narlaprevir (SCH900518) Merck Active site / linear On hold
PHX1766 Phenomix Active site Phase 1
ACH-1625 Achillion Active site / linear Phase 2
IDX320 Idenix Active site / macrocyclic On hold
MK-5172 Merck Active site / macrocyclic Phase 1
VX-985 Vertex Active site Phase 1
GS-9451 Gilead Active site Phase 1
Nucleos(t)ide NS5B polymerase inhibitors   
Valopicitabine (NM-283) Idenix / Novartis Active site / NM-107 Stopped
RG7128 Roche / Pharmasset Active site / PSI-6130 Phase 2
IDX184 Idenix Active site On hold
R1626 Roche Active site / R1479 Stopped
PSI-7977 Pharmasset Active site Phase 2
PSI-938 Pharmasset Active site Phase 1
INX-189 Inhibitex Active site Phase 1
Non-nucleoside NS5B polymerase inhibitors   
BILB 1941 Boehringer Ingelheim NNI site 1 / thumb 1 Stopped
BI 207127 Boehringer Ingelheim NNI site 1 / thumb 1 Phase 2
MK-3281 Merck NNI site 1 / thumb 1 Stopped
Filibuvir (PF-00868554) Pfizer NNI site 2 / thumb 2 Phase 2
VX-916 Vertex NNI site 2 / thumb 2 On hold
VX-222 Vertex NNI site 2 / thumb 2 Phase 2
VX-759 Vertex NNI site 2 / thumb 2 Phase 1
ANA598 Anadys NNI site 3 / palm 1 Phase 2
ABT-333 Abbott NNI site 3 / palm 1 Phase 2
ABT-072 Abbott NNI site 3 / palm 1 Phase 2
Nesbuvir (HCV-796) ViroPharma / Wyeth NNI site 4 / palm 2 Stopped
Tegobuvir (GS-9190) Gilead NNI site 4 / palm 2 Phase 2
IDX375 Idenix NNI site 4 / palm 2 Phase 1
NS5A inhibitors    
BMS-790052 Bristol-Myers Squibb NS5A domain 1 inhibitor Phase 2
BMS-824393 Bristol-Myers Squibb NS5A inhibitor Phase 1
AZD7295 AstraZeneca NS5A inhibitor Phase 1
PPI-461 Presidio NS5A inhibitor Phase 1
Indirect inhibitors / unknown mechanism of action   
NIM811 Novartis Cyclophilin inhibitor Stopped
SCY-635 Scynexis Cyclophilin inhibitor Phase 1
Alisporivir (Debio-025) Debiopharm / Novartis Cyclophilin inhibitor Phase 2
Alinia (nitazoxanide) Romark PKR induction ? Phase 2
Celgosivir BioWest Alpha-glucosidase inhibitor Stopped
New formulations of current therapies   
Taribavirin Valeant / ribavirin Phase 2
Locteron (BLX-883) Biolex Interferon receptor type 1 Phase 2
PEG-rIL-29 (peginterferon lambda) ZymoGenetics / BMS Interferon receptor type 3 Phase 2
Joulferon (albinterferon alfa-2b) HGS / Novartis interferon receptor type 1 Stopped